Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
703 (USA) · Dr. Okafor
consented 2013-11-21
AEs
1
Serious
0
Dropout signal
–
Adverse events
moderate
assessed
Moderate ARTHRITIS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-12-28 (study day 38.0); relationship: NONE
Data queries
No data queries.